



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/843185/2018

European Medicines Agency decision P/0402/2018

of 7 December 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bupivacaine (EMEA-000877-PIP03-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0402/2018

of 7 December 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bupivacaine (EMA-000877-PIP03-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Pacira Ltd on 26 February 2018 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 November 2018, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for bupivacaine, suspension for injection, perineural use, infiltration use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for bupivacaine, suspension for injection, perineural use, infiltration use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for bupivacaine, suspension for injection, perineural use, infiltration use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Pacira Ltd, Wessex House, Marlow Road, SL8 5SP - Bourne End, United Kingdom.

EMA/PDCO/566138/2018
London, 16 November 2018

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-000877-PIP03-17

Scope of the application

Active substance(s):

Bupivacaine

Condition(s):

Postsurgical analgesia

Pharmaceutical form(s):

Suspension for injection

Route(s) of administration:

Perineural use

Infiltration use

Name/corporate name of the PIP applicant:

Pacira Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Pacira Ltd submitted for agreement to the European Medicines Agency on 26 February 2018 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 3 April 2018.

Supplementary information was provided by the applicant on 13 August 2018. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Postsurgical analgesia

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- suspension for injection, perineural and infiltration use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition:

Postsurgical analgesia

2.1.1. Indication(s) targeted by the PIP

Local or regional analgesia when administered into the surgical site or as a nerve block in children from 1 to less than 18 years of age.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Suspension for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	4	Study 1 Multicentre, randomised, open-label, ropivacaine-controlled study to evaluate the pharmacokinetics, safety and efficacy of liposomal bupivacaine (hereinafter: Exparel) for postsurgical analgesia in paediatric subjects aged 6 to less than 18 years undergoing spine or cardiac surgeries (402-C-WI1)

		Study 2 Multicentre, open-label, randomised, ropivacaine-controlled study to evaluate the pharmacokinetics, safety and efficacy of Exparel for postsurgical analgesia in paediatric subjects aged 1 to less than 6 years undergoing hernia repair surgeries (TAP block) (402-C-WI2) Study 3 Multicentre, open-label, randomised, ropivacaine-controlled study to evaluate the safety and pharmacokinetics of Exparel when administered as a nerve block for surgical procedures like anterior cruciate ligament (ACL) repair, upper or lower extremity fractures in paediatric subjects aged 6 to less than 18 years (402-C-NB1) Study 4 Multicentre, open-label, randomised, ropivacaine-controlled study to evaluate the safety and pharmacokinetics of Exparel in paediatric subjects aged 1 to less than 6 years when administered as a nerve block for surgical procedures like repair of fractured femoral shaft (femoral block), hand or forearm surgery (axillary block), or inguinal hernia repair (ilio-inguinal block) (402-C-NB2)
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By April 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes